Dr Agarwals Health Care Ltd (AGARWALEYE) — shareholding pattern, promoter holding, financials and share price
About Dr Agarwals Health Care Ltd (AGARWALEYE)
Dr Agarwals Health Care Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as AGARWALEYE and on the BSE under scrip code 544350. Its ISIN is INE943P01029.
Incorporated in 2010, [1] Dr. Agarwal’s Health Care offers a wide array of eye care services, which include cataract and refractive surgeries, consultations, diagnoses, and non-surgical treatments. Additionally, they provide optical products, contact lenses, accessories, and pharmaceutical items related to eye care. [2]
Dr. Agarwal's Health Care Limited is India's largest eye care services chain, providing comprehensive medical services for ocular health including consultations, surgeries, and specialized treatments.
The company experienced strong financial performance with a 20.8% revenue growth YTD December 2025, driven by the expansion of operational facilities and introduction of advanced surgical technologies.
Listed peers in Hospital: Rainbow Childrens Medicare Ltd, Park Medi World Ltd, Healthcare Global Enterprises Ltd, Jupiter Life Line Hospitals Ltd, Yatharth Hospital & Trauma Care Services Ltd, Kovai Medical Center & Hospital Ltd.
Valuation & Returns
10 Jul 2026At ₹483.4 a share on 10 Jul 2026, Dr Agarwals Health Care Ltd (AGARWALEYE) was valued at a price-to-earnings ratio of 91.13x against an industry P/E of 61.73x and a price-to-book of 8.21x on a book value of ₹58.89 per share as of Mar 2025. Solomo computes return on equity of 9.01% and return on capital employed of 11.99% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 91.13x
- Industry P/E
- 61.73x
- P/B
- 8.21x
- EPS (TTM)
- ₹5.3
- Book value / share
- ₹58.89
- ROE
- 9.01%
- ROCE
- 11.99%
- ROA
- 4.58%
- Debt / equity
- 0.51x
- Dividend yield
- 0%
- EBITDA margin
- 29.58%
- 52-week range
- ₹402.1 – ₹567.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Dr Agarwals Health Care Ltd (AGARWALEYE) reported revenue of ₹2,080 crore, net profit of ₹168 crore and earnings per share of ₹4.2. That compares with revenue of ₹1,711 crore and net profit of ₹110 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹564 crore and net profit ₹50 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 696 | 1,018 | 1,332 | 1,711 | 2,080 |
| Net profit (₹ cr) | 43 | 103 | 95 | 110 | 168 |
| EPS (₹) | - | - | - | 2.64 | 4.2 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 33.31% | 42.39% | 28.44% |
| Profit growth | - | - | 16.09% |
| Stock price CAGR | - | - | 14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 32.34% of Dr Agarwals Health Care Ltd (AGARWALEYE) (down 0.02 pp QoQ), foreign institutional investors (FII) hold 57.96% and domestic institutional investors (DII) hold 7.72%. Market capitalisation was ₹15,323 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2025.
Largest disclosed public shareholders in Jun 2026: HYPERION INVESTMENTS PTE. LTD. 23.09%, CLAYMORE INVESTMENTS (MAURITIUS) PTE. LTD 10.19%, ARVON INVESTMENTS PTE.LTD. 9.87%, GOVERNMENT OF SINGAPORE 6.35%, INVESCO INDIA FLEXI CAP FUND 3.02%, POLAR CAPITAL FUNDS PLC - HEALTHCARE OPPORTUNITIES 1.62%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 32.34% | - | 57.96% | 7.72% | 67.66% |
| Mar 2026 | 32.36% | - | 57.94% | 7.83% | 67.64% |
| Dec 2025 | 32.39% | - | 58.06% | 7.78% | 67.61% |
| Sep 2025 | 32.42% | - | 58.13% | 7.92% | 67.58% |
| Jun 2025 | 32.42% | - | 59.26% | 6.44% | 67.58% |
| Mar 2025 | 32.45% | - | 60.62% | 5.21% | 67.55% |